Clinical ProgressBioCardia's primary focus remains the clinical and regulatory progress of CardiAMP HF in the U.S. and in Japan.
Regulatory ApprovalPotential approval of proprietary biotherapeutic delivery device should strengthen financial position and support clinical progress.